Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evommune, Inc.EVMN · Entity 5539 | Director · 10% owner | December 19, 2025 | December 22, 2025 |
| Rallybio CorpRLYB · Entity 6838 | Director | October 12, 2026 | October 14, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 02, 2021 | June 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evommune, Inc.
Report date December 19, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 4,026 |
Reported balance
After 2025-12-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-19 · Purchase · Acquired 1,000 · Balance 4,026 F1: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy NFLS Delta III Limited | 1,441,032 |
Reported balance
Holding disclosure · report date 2025-12-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,441,032 F2: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Pivotal bioVenture Partners Fund I, L.P. | 1,632,441 |
Reported balance
Holding disclosure · report date 2025-12-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,632,441 F3: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Pivotal bioVenture Partners Fund II, L.P. | 294,502 |
Reported balance
Holding disclosure · report date 2025-12-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 294,502 F4: Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F2: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4: Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Rallybio Corp
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,820 |
Ending reported balance
After 2026-10-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-12 · Exercise / conversion · Acquired 9,196 · Balance 9,196 Row 2 · 2026-10-12 · Exercise / conversion · Acquired 3,562 · Balance 12,758 Row 3 · 2026-10-12 · Exercise / conversion · Acquired 2,062 · Balance 14,820 |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-12 · Exercise / conversion · Disposed 9,196 · Balance 0 F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500. F1: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2035-05-13 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Exercise / conversion · Disposed 3,562 · Balance 0 F3: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.28 · Expires 2034-05-15 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-12 · Exercise / conversion · Disposed 2,062 · Balance 0 F4: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.
F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.
F3: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.
F4: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.
Vaxcyte, Inc.
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.49 · Expires 2031-06-01 | Direct | 15,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Disposed 15,000 · Balance 15,000 F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inozyme Pharma, Inc.
Report date July 01, 2025 · Filed July 03, 2025
Section 16 reporting ended · disclosed 2025-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Pivotal | 0 |
Reported balance
After 2025-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-01 · Other · Disposed 2,923,110 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. F3: Held directly by Pivotal bioVenture Partners Fund I, L.P. F4: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). F5: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Pivotal | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-07-01 · Other · Disposed 1,571,741 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. F4: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). F5: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein. F6: Held directly by Pivotal bioVenture Partners Fund II, L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F3: Held directly by Pivotal bioVenture Partners Fund I, L.P.
F4: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
F5: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
F6: Held directly by Pivotal bioVenture Partners Fund II, L.P.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2021 Filed Feb 11, 2021 00:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 93,740 | $28.75 | $2,695,025.00 |
DisclosureSEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,483,576 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.11, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 88,756 | $28.07 | $2,491,380.92 |
DisclosureSEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,577,316 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.49, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 38,248 | $27.12 | $1,037,285.76 |
DisclosureSEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,666,072 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.49, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 28,922 | $26.06 | $753,707.32 |
DisclosureSEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,704,320 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.18, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 50,874 | $25.64 | $1,304,409.36 |
DisclosureSEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,733,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.02 to $26.01, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8), (9), (10) and (11) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,768 | $25.06 | $69,366.08 |
DisclosureSEC source: 0001062993-21-000894 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,784,116 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 14,234 | $25.13 | $357,700.42 |
DisclosureSEC source: 0001062993-21-000894 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,786,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.56, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 17:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,000 | $25.07 | $50,140.00 |
DisclosureSEC source: 0001062993-21-000781 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,801,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.22, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnotes (2) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 27, 2021 Filed Jan 27, 2021 23:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,140 | $25.30 | $54,142.00 |
DisclosureSEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,803,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.04 to $26.62, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 23:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,373 | $26.13 | $35,876.49 |
DisclosureSEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,805,258 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.60, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 23:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 16,769 | $25.23 | $423,081.87 |
DisclosureSEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,806,631 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 23:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15,461 | $26.07 | $403,068.27 |
DisclosureSEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,823,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.27, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 23:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 19,511 | $25.61 | $499,676.71 |
DisclosureSEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,838,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,383 | $25.16 | $286,396.28 |
DisclosureSEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,858,372 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.58, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 100 | $25.11 | $2,511.00 |
DisclosureSEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,869,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 19,046 | $25.35 | $482,816.10 |
DisclosureSEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,869,855 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.77, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,000 | $26.05 | $182,350.00 |
DisclosureSEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,888,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.35, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 42,516 | $25.55 | $1,086,283.80 |
DisclosureSEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,895,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,808 | $26.05 | $99,198.40 |
DisclosureSEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,938,417 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.15, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 22,869 | $25.74 | $588,648.06 |
DisclosureSEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,942,225 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.03 to $26.02, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 14,918 | $25.88 | $386,077.84 |
DisclosureSEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,965,094 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.41 to $26.35, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,100 | $26.34 | $81,654.00 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 7 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,980,012 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.42, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 26,010 | $25.90 | $673,659.00 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 6 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,983,112 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.25, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 901 | $27.05 | $24,372.05 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,009,122 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.90 to $27.36, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 17,666 | $26.35 | $465,499.10 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,010,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.90 to $26.89, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 12,206 | $27.02 | $329,806.12 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,027,689 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.08, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 24,980 | $26.69 | $666,716.20 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,039,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.99, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 12,480 | $25.42 | $317,241.60 |
DisclosureSEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,064,875 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 200 | $28.23 | $5,646.00 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 8 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,077,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,944 | $27.08 | $242,203.52 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 7 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,077,555 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.99, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 31,468 | $26.43 | $831,699.24 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 6 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,086,499 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.99, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 469 | $29.51 | $13,840.19 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,117,967 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.34 to $29.53, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 22,587 | $28.80 | $650,505.60 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,118,436 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.34 to $29.33, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 24,524 | $27.75 | $680,541.00 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,141,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.34 to $28.33, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 22,507 | $29.99 | $674,984.93 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,165,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $30.50, inclusive. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 34,913 | $29.24 | $1,020,856.12 |
DisclosureSEC source: 0001062993-21-000219 · form4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,188,054 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $29.59, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4. F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:11 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 10,489,510 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020566 · doc4.xml · derivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,403,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Dr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:11 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | PurchaseCommon Stock | 187,500 | $16.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-20-020566 · doc4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,591,154 F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Dr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:11 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionCommon Stock | 1,403,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020566 · doc4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,403,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Dr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:47 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020395 · doc4.xml · derivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionSeries D Preferred Stock · Derivative | 211,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · derivative · entry 7 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 211,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_price: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionSeries C Preferred Stock · Derivative | 226,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · derivative · entry 6 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 226,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionSeries B Preferred Stock · Derivative | 1,692,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · derivative · entry 5 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,692,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_price: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | PurchaseCommon Stock | 93,000 | $16.00 | $1,488,000.00 |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · nonDerivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,222,967 F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionCommon Stock | 211,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · nonDerivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 2,129,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionCommon Stock | 226,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,918,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | ConversionCommon Stock | 1,692,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-037087 · doc4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P. Disclosed balance after: 1,692,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036736 · doc4.xml · derivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.